Skip to main content
  • ShortCut Device Meets Initial Safety, Efficacy Endpoints in Patients at High Risk for Coronary Obstruction: Pivotal Study

    In patients who are set to undergo transcatheter aortic valve replacement (TAVR) and are at-risk for coronary obstruction, the ShortCut leaflet modification device is safe and achieves success in leaflet splitting, and is associated with positive clinical outcomes, a new study shows. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details